 ️ US Insiders Are Buying Biotech — What Do They See? Analysis of the largest insider purchases on May 11, 2026. Numbers that make you think. Top 3 by volume: - Genedx Holdings (WGS) — Director Keith Meister invested $46.8 million at $38.84. Stake increased by 34%. Genetic testing — a sector insiders see as growing. - Odyssey Therapeutics (ODTX) — Two purchases at once: Director Li Nan for $20 million and Sr One Capital for $10 million. Total $30 million at $18. Therapeutic biopharma. - Pulse Biosciences (PLSE) — Robert Duggan added $13 million at $19.69. Already owns 49 million shares, but continues to increase. What stands out: - Biotech dominates (WGS, ODTX, PLSE, ATRA, COAG, MOBI) — 6 out of top 10 - Mobia Medical (MOBI) — Two insiders bought, one of them a new shareholder (+61% to stake) - Atara Biotherapeutics (ATRA) — Purchase for $4.7 million (+49%) - Starlink AI Acquisition (OTAI) — AI SPAC, $2.2 million Less obvious: - OLED (Universal Display) — CEO bought for $1 million. First time in a long while. - Norwegian Cruise Line (NCLH) — Director for $521k. Tourism is recovering. - Lamb Weston (LW) — CFO bought for $409k. French fries = bet on consumption. My position: When directors and 10% owners synchronously enter a sector, it's a signal. Biotech is currently at decent discounts after the correction. But I don't enter without Due Diligence — I analyze each case separately. By the way, my AI agent collects such data in real time. If you're curious about what's brewing — https://asibiont.com